EU places China's Zhejiang Huahai under increased supervision
European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan. (Source: Reuters: Health)
Source: Reuters: Health - October 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug? Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
Evidence suggests that sacubitril/valsartan may have antiarrhythmic effects. What does this mean for prevention of sudden death?Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Diovan HCT (Valsartan and Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 3, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Freezes Imports From Chinese Maker of Tainted Valsartan FDA Freezes Imports From Chinese Maker of Tainted Valsartan
The FDA's import alert bans all ingredients and finished drug products made by Zhejiang Huahai Pharmaceuticals from legally entering the United States.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 28, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

FDA Bans Import of Meds From Chinese Firm
The 'import alert' from the FDA against Zhejiang Huahai Pharmaceuticals comes after a series of recalls for valsartan heart and blood pressure drugs that include ingredients made by ZHP. (Source: WebMD Health)
Source: WebMD Health - September 28, 2018 Category: Consumer Health News Source Type: news

Losartan vs. Valsartan (Differences between Side Effects and Uses)
Title: Losartan vs. Valsartan (Differences between Side Effects and Uses)Category: MedicationsCreated: 9/21/2018 12:00:00 AMLast Editorial Review: 9/21/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 21, 2018 Category: Drugs & Pharmacology Source Type: news

Safe to Start Sacubitril/Valsartan Predischarge in Acute HF Safe to Start Sacubitril/Valsartan Predischarge in Acute HF
In first of its kind data from the TRANSITION trial, patients safely tolerated the early-initiation strategy as well as the recommended practice of starting the uptitration process after discharge.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 18, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Regulators find second cancer-linked chemical in recalled drug
A closer inspection of valsartan, a commonly used blood pressure medication, has uncovered traces of a second toxin. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 17, 2018 Category: Pharmaceuticals Source Type: news

FDA Finds Another Carcinogen in Certain Valsartan Heart Meds
Title: FDA Finds Another Carcinogen in Certain Valsartan Heart MedsCategory: Health NewsCreated: 9/14/2018 12:00:00 AMLast Editorial Review: 9/17/2018 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - September 17, 2018 Category: Cardiology Source Type: news

Daily aspirin not beneficial in healthy adults
Trial looks at risks and benefits of aspirin Related items fromOnMedica Too few women take part in many CVD clinical trials US doctor says FDA should have withdrawn rosuvastatin GPs defend practice on prescribing statins Drugs regulators “put profits before patients” Withdrawn valsartan meds not linked to short-term cancer risk (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 17, 2018 Category: UK Health Source Type: news

FDA Finds Another Carcinogen in Certain Valsartan Heart Meds
FRIDAY, Sept. 14, 2018 -- The U.S. Food and Drug Administration warns that it has found a second impurity in three lots of Torrent Pharmaceuticals'valsartan drug products. The FDA first recalled valsartan medicines back in July, after the Chinese... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2018 Category: Pharmaceuticals Source Type: news

Second Contaminant Found in Valsartan Drugs
Those drugs were already part of August’s recall of valsartan products for possible contamination with NDMA, another impurity that may cause cancer. (Source: WebMD Health)
Source: WebMD Health - September 14, 2018 Category: Consumer Health News Source Type: news

No Early Cancer Risk Seen from Contaminated Valsartan
(MedPage Today) -- Cohort study reassures, but FDA notes a second contaminant (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 14, 2018 Category: American Health Source Type: news

FDA Finds Another Carcinogen in Certain Valsartan Heart Meds
FRIDAY, Sept. 14, 2018 -- There's more bad news for Americans who took certain brands of the common blood pressure medication valsartan. The U.S. Food and Drug Administration on Thursday warned that it has found a second impurity in three lots of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2018 Category: General Medicine Source Type: news

No Short-Term Cancer Risk From Recalled Heart Med Valsartan: Study
Title: No Short-Term Cancer Risk From Recalled Heart Med Valsartan: StudyCategory: Health NewsCreated: 9/13/2018 12:00:00 AMLast Editorial Review: 9/14/2018 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - September 14, 2018 Category: Cardiology Source Type: news

FDA finds another impurity in recalled heart drug
The US Food and Drug Administration said it found additional "unexpected impurity" in three lots of Torrent Pharmaceuticals' recalled valsartan drug. (Source: CNN.com - Health)
Source: CNN.com - Health - September 14, 2018 Category: Consumer Health News Source Type: news

FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm ’s already recalled products
FDA update on the ongoing investigation into valsartan impurities, recalls and current findings. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 13, 2018 Category: American Health Source Type: news

Tainted Valsartan Not Linked to Cancer Risk in the Short Term Tainted Valsartan Not Linked to Cancer Risk in the Short Term
An expedited short-term analysis finds no increased risk for cancer in patients who took NDMA-contaminated valsartan, but uncertainty remains for colorectal and uterine cancer. The EMA weighs in.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

No Apparent Short-Term Cancer Risk From Recalled Valsartan
THURSDAY, Sept. 13, 2018 -- Users of valsartan contaminated with N-nitrosodimethylamine (NDMA) seem not to have increased cancer risk, according to a study published online Sept. 12 in The BMJ. Anton Potteg ård, Ph.D., from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 13, 2018 Category: Pharmaceuticals Source Type: news

FDA, EMA Valsartan Update, New Data on Cancer Risk FDA, EMA Valsartan Update, New Data on Cancer Risk
The FDA and EMA report a possible second carcinogen in previously withdrawn vasartan products, while a new analysis finds no increased cancer risk in those who previously took contaminated valsartan.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 13, 2018 Category: Cardiology Tags: Cardiology News Source Type: news

No Short-Term Cancer Risk From Recalled Valsartan
The U.S. Food and Drug Administration in July recalled valsartan medicines manufactured by the Chinese company Zhejiang Huahai Pharmaceuticals. (Source: WebMD Health)
Source: WebMD Health - September 13, 2018 Category: Consumer Health News Source Type: news

No Short - Term Cancer Risk From Recalled Heart Med Valsartan: Study
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 13, 2018 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Oncology, Pharmacy, News, Source Type: news

2nd possible carcinogen found in recalled blood pressure drug valsartan, Health Canada says
A second impurity that is a classified as a probable human carcinogen has been found in valsartan, manufactured by Zhejiang Huahai Pharmaceuticals in China, Health Canada announces. (Source: CBC | Health)
Source: CBC | Health - September 13, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

No Short-Term Cancer Risk From Recalled Heart Med Valsartan: Study
THURSDAY, Sept. 13, 2018 -- People who took recalled blood pressure drugs containing a carcinogen do not appear to have a markedly increased short-term risk of cancer, a new study reports. Doctors are reluctant to say they're fully in the clear,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 13, 2018 Category: General Medicine Source Type: news

Withdrawn valsartan meds not linked to short-term cancer risk
Expedited analysis of NDMA-contaminated products finds no markedly raised short-term cancer risk Related items fromOnMedica GPs defend practice on prescribing statins Too few women take part in many CVD clinical trials MHRA tightens licence restrictions on valproate for women Cancer patients using complementary meds die sooner Drugs regulators “put profits before patients” (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 13, 2018 Category: UK Health Source Type: news

No Short-Term Cancer Risk From Recalled Heart Med Valsartan: Study
(Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - September 13, 2018 Category: Cancer & Oncology Source Type: news

Blood pressure pills recalled worldwide 'does NOT boost the risk of cancer'
Researchers from the University of Southern Denmark found that people who take the medicine valsartan for around four years are not more likely to develop cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - September 12, 2018 Category: Consumer Health News Source Type: news

After valsartan recall, study offers 'modest reassurance' on cancer risk
(Source: CNN.com - Health)
Source: CNN.com - Health - September 12, 2018 Category: Consumer Health News Source Type: news

Valsartan Tablets (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 10, 2018 Category: Drugs & Pharmacology Source Type: news

FDA warns blood pressure drugs investigation for cancer-causing chemical
The FDA is investigating a broader set of medications that may be repackaged valsartan after recalling the popular blood pressure drug over its discovery that it contains a carcinogen, the agency said today. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2018 Category: Consumer Health News Source Type: news

FDA investigation into heart drug valsartan may lead to more recalls
The US Food and Drug Administration said Thursday that it is conducting an extensive investigation into an entire class of drugs over potential cancer risk. (Source: CNN.com - Health)
Source: CNN.com - Health - August 30, 2018 Category: Consumer Health News Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on FDA ’s ongoing investigation into valsartan impurities and recalls and an update on FDA’s current findings
FDA update on the ongoing investigation into valsartan impurities, recalls and current findings. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 30, 2018 Category: American Health Source Type: news

Recall of heart drug valsartan continues to expand
The US Food and Drug Administration has again expanded the list of recalled medications that contain valsartan, used as a component in a set of drugs to treat heart failure and blood pressure. (Source: CNN.com - Health)
Source: CNN.com - Health - August 28, 2018 Category: Consumer Health News Source Type: news

Toxin At Heart Of Drug Recall Shows Holes in Medical Safety Net Toxin At Heart Of Drug Recall Shows Holes in Medical Safety Net
A toxin inadvertently produced in the manufacture of the widely prescribed medicine valsartan but not spotted for years raises questions about regulators'ability to detect risks in a sprawling global drug supply chain increasingly reliant on factories in China.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 24, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets
Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer ...
Source: Food and Drug Administration - August 22, 2018 Category: Food Science Source Type: news

UPDATED:ADDITIONAL LOTS ADDED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets
Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer ...
Source: Food and Drug Administration - August 22, 2018 Category: Food Science Source Type: news

Health Canada expands recall of some heart, high blood pressure drugs
Health Canada has added eight more products to its recall of certain medications containing valsartan, a drug used to treat high blood pressure and heart failure, after probable carcinogens were found in some. (Source: CBC | Health)
Source: CBC | Health - August 20, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets
Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 18, 2018 Category: Food Science Source Type: news

More Drug Makers Tagged as Valsartan Recall Grows
More than 20 European countries, Canada, and the United States have recalled valsartan medications in recent weeks after NDMA was discovered in the drugs’ ingredients manufactured by Zhejiang Huahai Pharmaceuticals of Linhai, China. (Source: WebMD Health)
Source: WebMD Health - August 13, 2018 Category: Consumer Health News Source Type: news

Tainted Valsartan Recall Expands
as More Drug Makers Implicated (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 13, 2018 Category: General Medicine Source Type: news

India ’s Hetero pulls heart drug from U.S. amid cancer risk probes
A unit of India ’s Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug. (Source: Reuters: Health)
Source: Reuters: Health - August 11, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Tainted Valsartan Recall Expands as More Drug Makers Implicated Tainted Valsartan Recall Expands as More Drug Makers Implicated
News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Skeptical Cardiologist: Where Are My Generic Meds Made?
(MedPage Today) -- Valsartan recall prompts a look by Anthony Pearson, MD (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 10, 2018 Category: American Health Source Type: news

Valsartan Recall Expanded, FDA Investigating Products from Outside China
(MedPage Today) -- Other ARB manufacturers subject to FDA investigation (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 10, 2018 Category: Cardiology Source Type: news

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)
As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer). (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 9, 2018 Category: Food Science Source Type: news

FDA Expands Recall Of Common Blood Pressure Drug Over Cancer Concern
(CNN) — The US Food and Drug Administration expanded the list of drugs being recalled that contain valsartan. The drug is used as a component in a set of drugs used to treat heart failure and blood pressure. The FDA initially announced a valsartan recall in July after lab tests discovered that some drugs could have been tainted with a substance linked to higher risk of cancer. The drug had previously been recalled in 22 other countries. The expanded recall includes some drugs that contain valsartan and hydrochlorothisazide. Not all of the drugs containing valsartan were impacted. N-nitrosodimethylamine or NDMA, the i...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 8, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News Local TV Recall Valsartan Source Type: news

FDA expands recall of blood pressure drug valsartan due to cancer concern
The US Food and Drug Administration expanded the list of drugs being recalled that contain valsartan. The drug is used as a component in a set of drugs used to treat heart failure and blood pressure. (Source: CNN.com - Health)
Source: CNN.com - Health - August 8, 2018 Category: Consumer Health News Source Type: news

FDA expands recall of common heart medication Valsartan
A common heart medication may contain a cancer-causing chemical, the FDA said. (Source: ABC News: Health)
Source: ABC News: Health - August 7, 2018 Category: Consumer Health News Tags: Health Source Type: news

Valsartan Tablets (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - August 2, 2018 Category: Drugs & Pharmacology Source Type: news

Sacubitril/valsartan cost  effective for heart failure in Germany
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2018 Category: Drugs & Pharmacology Source Type: news